| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 184.03 | 2.3% | 3.2% |
| Total Income | 192.60 | 3.5% | 4.5% |
| Expenditure | 175.15 | 2.2% | 5.3% |
| PBT | 17.45 | 19.2% | 2.0% |
| Net Profit | 13.28 | 37.9% | 1.9% |
| OPM | 9.39% | 0.55pp | 0.14pp |
| NPM | 6.89% | 1.72pp | 0.18pp |
| EPS | 2.36 | 15.1% | 2.5% |
Revenue beats guidance, but margins miss; H2 execution critical
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
H1 beat revenue guidance, but EBITDA margins fell 200-300 bps below range. Q2 execution miss acknowledged.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
JNK beat H1 revenue guidance (30.4% vs 20-25%) but missed margin targets (H1 EBITDA 10.6% vs 12-14%). Q2 suffered from execution delays (₹30-40 Cr deferred), raising H2 pressure. Large order wins (₹500 Cr Nigeria, ₹830 Cr domestic flares) provide visibility, but pipeline conversion and margin recovery remain key risks. Management maintains FY27 guidance but faces execution credibility test in Q3-Q4.
₹184 Cr
Revenue · +3.2% YoY₹13.3 Cr
Reported PAT · +2% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
H1 revenue growth 30.4% YoY, beats guidance
METH1 revenue ₹370.2 Cr vs ₹283.9 Cr prior year = 30.4%. FY27 guidance 20-25%.
Q2 EBITDA margin 11.1%, within 12-14% guidance
MISSQ2 EBITDA ₹20.8 Cr / ₹187.5 Cr revenue = 11.1%. Guidance range 12-14%. Below range.
₹30-40 Cr deferred revenue from Q2 monsoon/logistics delays
METManagement cited shipment delays and monsoon disruptions. Specific deferral amount cited.
Order book ₹1,662 Cr as of Sept 30, 2026; pipeline ₹5,000 Cr
OVERSTATEDNo external validation in call; consistent with prior ₹1,801 Cr guidance. Pipeline increased from ₹6,000 Cr (prior guidance) to ₹5,000 Cr stated.
Large international orders: ₹500 Cr Nigeria (JNK Global), ₹830 Cr domestic flares
METNigeria ₹500 Cr declared to stock exchange; domestic ₹830 Cr also claimed. Order book now includes these.
Earnings quality
What changed since the last call
Bidding pipeline revised downward
DowngradePrior guidance ₹6,000 Cr; now stated as ₹5,000 Cr. No explanation given. Narrows growth base.
Large Nigeria order secured
Upgrade₹500 Cr Nigeria refinery heater package from JNK Global (repeat customer). Adds near-term visibility.
EBITDA margin guidance reaffirmed despite H1 miss
NeutralH1 EBITDA 10.6% vs 12-14% guidance. Management reaffirmed FY27 guidance, betting on margin recovery in H2.
Execution challenges cited for Q2
DowngradeMonsoon, logistics delays caused ₹30-40 Cr Q2 deferral. Shifts execution risk to H2.
The Q&A
Analysts pressed hard on deferral specifics (₹30-40 Cr), Dangote scope uncertainty, and non-heater pipeline timing. Management defended via seasonality narrative (H2 historically 60-65% of revenue) and timeline hedges (2-3 month Kenya inquiries, 4-5 month Dangote finalization). CFO candid on execution challenges but firm on FY27 guidance.
Deferral quantum and recovery — Shubham Borade, ICICI Securities
AnsweredH1 up 30% already; H2 traditionally 60-65% of revenue. ₹30-40 Cr deferred from Q2, executable in H2. Order book ₹1,662 Cr provides foundation.
H2 executability — Deepak Purswani, SVAN Investments
PartialSupply order is ₹500 Cr declared. Balance scope exists per Dangote declaration; could be ₹300-600 Cr. Still under discussion, timeline 2-3 months for clarity.
Kenya refinery timing — Deepak Purswani, SVAN Investments
AnsweredInquiries expected in 2-3 months. Discussion with BPCL likely to start December; ordering 6-8 months post-FID approval. Not in ₹5,000 Cr pipeline yet.
Non-heater pipeline details — Kamlesh Jain, Lotus Asset Managers
Answered₹2,500 Cr non-heater opportunities. ₹1,000 Cr already bid/under discussion; ₹1,500 Cr to be bid soon. Could finalize in next two quarters.
BPCL Vizag refinery — Rupesh Tatiya, Long Equity Partners
AnsweredFID approval still pending. Tenders likely 6-8 months post-FID; ordering expected in 12 months. Not yet in ₹5,000 Cr pipeline.
Chemdist subsidiary growth — Rupesh Tatiya, Long Equity Partners
PartialChemdist order book ~₹20 Cr currently. Main focus is green hydrogen, green fuels, sustainable chemicals. These will take 2 years to materialize into larger projects.
Working capital and debt funding — Ram Modi, PL Capital
PartialWith customer payment terms and bank limits, should self-fund without additional debt. No specific plan yet needed.
Commodity price hedging — Ram Modi, PL Capital
AnsweredSome contracts have price variation clauses (e.g., PSU contracts). For others, it's a business risk. Minimal hedging strategies in place.
Order disclosure range — Ram Modi, PL Capital
PartialCFO acknowledged; will narrow range going forward. Currently, exact value depends on client confidentiality; ₹300-600 is the realistic range for now.
Guidance
FY27 revenue growth 20-25% (reaffirmed)
MediumH1 already at 30.4%; H2 deferred revenue ₹30-40 Cr boosts likelihood. But execution risk remains.
EBITDA margin 12-14% on operational revenue (reaffirmed)
LowH1 actual 10.6%; Q2 at 11.1%. Below range. Input cost pressure cited; margin recovery bet on H2.
Risks the call surfaced
Execution delay risk
MediumQ2 suffered ₹30-40 Cr deferral from monsoon, logistics. H2 must absorb this + full planned revenue. Project-based model makes timing volatile.
Margin pressure
HighEBITDA margin 10.6% (H1) vs 12-14% guidance. Q2 at 11.1%. Cause not detailed; likely cost of raw materials (steel, copper, aluminum).
Pipeline conversion uncertainty
Medium₹5,000 Cr pipeline (₹2,500 Cr non-heating) is a target, not committed. Non-heating projects (green hydrogen, sustainable fuels) on 2+ year development cycles. Conversion risk high.
Large contingent order scope uncertainty
MediumNigeria ₹500 Cr declared to stock exchange. Balance scope (~₹300-600 Cr additional) is 'under discussion' with 2-3 month timeline. Not in order book; no certainty on total value.
International market readiness
LowKenya refinery (Dangote) still in FID approval stage; inquiries expected 2-3 months. BPCL Vizag FID pending. Timelines uncertain; projects 12+ months away from ordering.
Management
Score 6/10. CEO confident on order book and pipeline; CFO more cautious on specifics. Acknowledged execution challenges in Q2 honestly. Hedged on Dangote balance scope ('under discussion') and Kenya timeline (2-3 months). Not fully transparent on margin miss drivers. H1 beat revenue guidance (30.4% vs 20-25%); missed EBITDA margin (10.6% vs 12-14%). Q2 execution derailed by monsoon/logistics (₹30-40 Cr deferral). Maintains FY27 guidance despite challenges, betting on H2 recovery.
1 · Q3 FY27 (Oct-Dec 2026)
₹30-40 Cr deferred Q2 revenue expected to shift; H2 seasonally strong (60-65% of annual revenue traditionally)
2 · Nov 20, 2026
NTPC and ONGC bidding packages bid due; potential large domestic infrastructure orders
3 · Dec 2026 onwards
Kenya refinery inquiries expected (2-3 month timeline); Dangote Nigeria balance scope discussions (4-5 month finalization)
Management maintains FY27 guidance but faces execution credibility test in Q3-Q4.